AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant F
Description: Use of Myblu e-cigarette with flavor F 2.4% nicotine
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant G
Description: Use of Myblu e-cigarette with flavor G 4.0% nicotine
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Max Exercise Test
Description: Pedaling on a cycle ergometer to volitional fatigue.
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary Max Exercise Test
Description: Pedaling on a cycle ergometer to volitional fatigue.
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant H
Description: Use of Myblu e-cigarette with flavor H 3.6% nicotine
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire
Description: A 10 minute questionnaire that measures quality of life.
Study NCT02416024 — intervention group
Intervention type: DEVICE
Intervention: SphygmoCor system
Description: Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Questionnaire
Description: A 10 minute questionnaire that measures quality of life.
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal Exercise Test
Description: Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
Study NCT01627652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude
Description: the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
Study NCT04092205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Lipophilic, membrane passing Metal chelator and anti oxidant
Study NCT00558506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: intravenously 750mg (in patients with weight of 60- 100kg)
Study NCT02335554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodHacker
Description: Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
Study NCT02335554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Care
Description: Online information about depression from government and other trusted sources to educate users about depression.
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Submaximal Exercise Test
Description: Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
Study NCT02424201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: experimental
Study NCT02424201 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vitamin c
Description: control
Study NCT03169413 — intervention group
Intervention type: GENETIC
Intervention: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Description: Gene study
Study NCT01199133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dpte and Dfar Allergen Extracts
Description: 300 IR, once a day, for one year.
Study NCT01199133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once a day, for one year.
Study NCT03695757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A) Healthy subjects
Description: Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
Study NCT00329472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, cisplatin
Study NCT01120041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing counseling
Description: Motivational interviewing counseling given during the prenatal and postpartum phases
Study NCT01120041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing counseling
Description: Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
Study NCT01120041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing counseling
Description: Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
Study NCT01120041 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: Traditional health education given during the prenatal phase and the postpartum phase
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: A blood draw amounting to 1 teaspoon of blood drawn.
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Description: A blood draw amounting to 1 teaspoon of blood drawn.
Study NCT01815424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BID for 16 weeks and then re-randomized into active groups
Study NCT01815424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 5mg BID for 52 weeks
Study NCT01815424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10mg BID for 52 weeks
Study NCT05447390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Handgrip strength test
Description: The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
Study NCT03838614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)
Description: The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
Study NCT03695757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part B) Advanced solid tumor
Description: Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
Study NCT00701701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme® (alglucosidase alfa)
Description: Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.
Study NCT00701701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme® (alglucosidase alfa)
Description: Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
Study NCT03838614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmical auditory stimulation gait training (RAS)
Description: The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
Study NCT03838614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle power training (MPT)
Description: The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
Study NCT03838614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controls
Description: Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
Study NCT02869126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)
Description: * During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later
Study NCT02869126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Sestamibi
Description: First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy
Study NCT02869126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thallium-201
Description: Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy
Study NCT00565396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril and Losartan
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
Study NCT01127633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: 400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
Study NCT01127633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
Study NCT04116177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stimulation using VerciseTM system
Study NCT04116177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulation using VerciseTM system
Study NCT03917875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention
Description: The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
Study NCT01568281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole ODF
Description: Each volunteer will receive a single dose of Anastrozole ODF with water.
Study NCT01568281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimidex tablet
Description: Each volunteer will receive a single dose of Arimidex tablet with water
Study NCT01568281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole ODF
Description: Each volunteer will receive a single dose of Anastrozole ODF without water.
Study NCT02026947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Benzoate
Description: 0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
Study NCT02026947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02026947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02704624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
Study NCT02704624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
Study NCT01794624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy for Catastrophizing
Description: Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
Study NCT01794624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy for Sleep Continuity Disturbance
Description: Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
Study NCT03533699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Study NCT03533699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets with no active drug
Study NCT02078050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phrenic nerves magnetic stimulations
Study NCT02695017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iso inertial
Study NCT02695017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional machine
Study NCT06429046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIDOCAINE GEL
Description: To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
Study NCT06429046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COLD LIDOCAINE GEL
Description: In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 1
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 2
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 3
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 4
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 5
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 6
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose TBD
Description: Administered by subcutaneous injection
Study NCT03998514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT00614419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene Polypropylene Mesh
Description: The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
Study NCT00614419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Inguinal Hernia Matrix
Description: The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
Study NCT01958255 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: planned intervention for tobacco cessation counseling
Description: game session for rapport building followed by group discussion and tobacco cessation counseling
Study NCT02027727 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: no intervention- tihs is an observational study
Study NCT01344486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full conditioning
Description: addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
Study NCT01344486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pneumoperitoneum
Description: 100% carbon dioxide used for the pneumoperitoenum
Study NCT01861561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide
Description: Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
Study NCT01861561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose intravenous cyclophosphamide
Description: Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose
Study NCT03075852 — intervention group
Intervention type: DEVICE
Intervention: Heads- Up Display Surgery
Description: Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
Study NCT00194467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir
Description: 900 mg once a day for 8 weeks
Study NCT00194467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo, once a day for 8 weeks
Study NCT03320837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Infant formula
Description: Breast milk substitute containing synbiotics
Study NCT03320837 — intervention group
Intervention type: OTHER
Intervention: Breast milk
Description: Breast milk
Study NCT02544880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
Study NCT02544880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MUC1 Vaccine
Description: 300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
Study NCT02544880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Influenza Vaccine
Description: 300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.